Overexpression of MDM2 in leukemic cells in previously treated patients with chronic lymphocytic leukemia.

被引：0
|
作者：
Shinn, CA
Byrd, JC
Neuberg, DS
Flinn, IW
Grever, MR
机构：
[1] Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Baltimore, MD 21205 USA
[2] Walter Reed Army Med Ctr, Hematol Oncol Serv, Washington, DC 20307 USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2422
引用
收藏
页码：542A / 542A
页数：1
相关论文
共 50 条
  • [31] In vitro topoisomerase II DNA complex formation and cytotoxicity of etoposide in leukemic cells from patients with acute myelogenous and chronic lymphocytic leukemia.
    Wang, YY
    Zhou, R
    Liliemark, J
    Gruber, A
    Lindemalm, S
    Aibertioni, F
    Liliemark, E
    BLOOD, 1998, 92 (10) : 225A - 225A
  • [32] Optimization of metaphase yields of B cells in chronic lymphocytic leukemia.
    Siitonen, SM
    Larramendy, M
    Hurme, M
    Vilpo, L
    Knuutila, S
    Vilpo, JA
    BLOOD, 1997, 90 (10) : 3737 - 3737
  • [33] A phase I/II trial of Xcellerated T Cells™ in patients with chronic lymphocytic leukemia.
    Castro, JE
    Wierda, WG
    Kipps, TJ
    Keating, MJ
    Bole, J
    Anderson, B
    Meyer, J
    Bonyhadi, M
    Berenson, RJ
    Frohlich, MW
    BLOOD, 2004, 104 (11) : 687A - 688A
  • [34] Hypoplastic myelodysplastic syndrome with autoimmune phenomena supervening previously untreated chronic lymphocytic leukemia.
    Wajima, T
    BLOOD, 1998, 92 (10) : 272B - 272B
  • [35] MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells
    Coll-Mulet, Llorenc
    Iglesias-Serret, Daniel
    Santidrian, Antonio F.
    Cosialls, Ana M.
    de Frias, Merce
    Castano, Esther
    Campas, Clara
    Barragan, Montserrat
    Fernandez de Sevilla, Alberto
    Domingo, Alicia
    Vassilev, Lyubomir T.
    Pons, Gabriel
    Gil, Joan
    BLOOD, 2006, 107 (10) : 4109 - 4114
  • [36] A phase I/II study of Xcellerated T Cells in patients with chronic lymphocytic leukemia.
    Kipps, TJ
    Wierda, WG
    Castro, JE
    Keating, MJ
    Boccia, RV
    Steis, R
    Meyer, J
    Berenson, RJ
    Frohlich, MW
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 168S - 168S
  • [37] MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia
    Gryshchenko, Irina
    Hofbauer, Sebastian
    Stoecher, Markus
    Daniel, Peter T.
    Steurer, Michael
    Gaiger, Alexander
    Eigenberger, Karin
    Greil, Richard
    Tinhofer, Inge
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (14) : 2252 - 2257
  • [38] Pneumonias in patients with chronic lymphocytic leukemia.: Study of 30 episodes
    Batlle, M
    Ribera, JM
    Oriol, A
    Rodríguez, L
    Cirauqui, B
    Xicoy, B
    Grau, J
    Feliu, J
    Flores, A
    Millá, F
    MEDICINA CLINICA, 2001, 116 (19): : 738 - 740
  • [39] Genomic complexity identifies patients with agressive chronic lymphocytic leukemia.
    Malek, Sami N.
    Ouillette, Peter
    Erba, Harry
    Saddler, Chris
    Jakubowiak, Andrzej
    Kaminski, Mark
    Shedden, Kerby
    Kujawski, Lisa
    BLOOD, 2007, 110 (11) : 151A - 151A
  • [40] PBSC mobilization and immune selection in patients with chronic lymphocytic leukemia.
    Scimè, R
    Indovina, A
    Santoro, A
    Musso, M
    Olivieri, A
    Tringali, S
    Crescimanno, A
    Montanari, M
    Felice, R
    Catania, P
    Mariani, G
    Leoni, P
    Majolino, I
    BLOOD, 1998, 92 (10) : 307B - 307B
12345